tradingkey.logo
tradingkey.logo
検索

Nasus Pharma Ltd

NSRX
ウォッチリストに追加
3.640USD
+0.070+1.96%
終値 09-23 16:00ET
42.62M時価総額
損失額直近12ヶ月PER

Nasus Pharma Ltdについて 企業名

Nasus Pharma Ltd is an Israel-based pharmaceutical company. The Company conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The Company's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.

Nasus Pharma Ltd プロフィール

企業コードNSRX
会社名Nasus Pharma Ltd
上場日Aug 13, 2025
最高経営責任者「CEO」Teleman (Dan)
従業員数- -
証券種類Ordinary Share
決算期末Aug 13
本社所在地Yigal Alon 65
都市TEL AVIV-YAFO
証券取引所NASDAQ OMX – NASDAQ Basic Amex
Israel
郵便番号- -
電話番号97237326616
ウェブサイトhttps://www.nasuspharma.com
企業コードNSRX
上場日Aug 13, 2025
最高経営責任者「CEO」Teleman (Dan)

Nasus Pharma Ltdの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.92M
+1.20%
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.92M
+1.20%
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.92M
+1.20%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
--
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
--
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Dr. Galia Temtsin Kryaz, Ph.D.
Dr. Galia Temtsin Kryaz, Ph.D.
Director of CMC and Product Development
Director of CMC and Product Development
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Ronnie Hershman
Mr. Ronnie Hershman
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.92M
+1.20%
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.92M
+1.20%
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.92M
+1.20%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
--
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
--
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
--

よくある質問

Nasus Pharma Ltdの上位5名の株主は誰ですか?

Nasus Pharma Ltdの上位5名の株主は以下のとおりです。Mr. Udi Gilboa
tradingkey.logo
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。